Merck, Keytruda and Halozyme

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in
Merck injected version of Keytruda faces possible patent challenge: Report
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of
New version of Merck's cancer drug faces possible patent battle: reports
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.
BioSpace4d
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Devdiscourse2d
Reuters Health News Summary
According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.